Published in Br J Clin Pharmacol on November 01, 1983
In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol (1988) 1.44
Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol (2003) 1.21
Effects of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol (1984) 1.19
Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects. Br J Clin Pharmacol (1985) 1.05
The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. Br J Clin Pharmacol (1985) 1.04
Effect of oral contraceptive steroids on the clinical course of malaria infection and on the pharmacokinetics of mefloquine in Thai women. Bull World Health Organ (1988) 0.99
2-Hydroxylation of ethinyloestradiol in relation to the oxidation of sparteine and antipyrine. Br J Clin Pharmacol (1984) 0.87
Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria. Bull World Health Organ (1990) 0.79
The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis. Br J Clin Pharmacol (1985) 0.79
Cimetidine: interaction with oral anticoagulants in man. Lancet (1979) 4.67
Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol (1981) 3.07
Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology (1979) 2.31
A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine. J Steroid Biochem (1978) 1.90
Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers. Br J Clin Pharmacol (1979) 1.55
Assessment of the drug metabolism capacity of the liver. Br J Clin Pharmacol (1982) 1.51
Impairment of drug metabolism in man by allopurinol and nortriptyline. N Engl J Med (1970) 1.44
Differential effects of enzyme induction on antipyrine metabolite formation. Br J Clin Pharmacol (1982) 1.43
Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man. Br J Clin Pharmacol (1981) 1.32
The effect of spironolactone on antipyrine metabolism in man. Pharmacology (1973) 1.31
Assessment of urinary 6 beta-hydroxycortisol as an in vivo index of mixed-function oxygenase activity. Br J Clin Pharmacol (1981) 1.26
Imidazole derivatives--a new class of microsomal enzyme inhibitors. Biochem Pharmacol (1972) 1.17
Inhibition of drug metabolism by the antimalarial drugs chloroquine and primaquine in the rat. Biochem Pharmacol (1983) 1.09
Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. Clin Pharmacol Ther (1977) 1.04
Structure-activity relationships in the effects of 1-alkylimidazoles on microsomal oxidation in vitro and in vivo. Biochem Pharmacol (1974) 1.02
Effects of an oral contraceptive on hepatic size and antipyrine metabolism in premenopausal women. Clin Pharmacol Ther (1978) 1.01
Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor. Lancet (1971) 0.96
Steric factors in the inhibitory interaction of imidazoles with microsomal enzymes. Biochem Pharmacol (1977) 0.95
Urinary 17-hydroxycorticosteroid determination with p-hydrazinobenzenesulfonic acid-phosphoric acid. Am J Clin Pathol (1973) 0.94
Interaction between antipyrine and aminopyrine. Clin Pharmacol Ther (1976) 0.81
Artemisinins target the SERCA of Plasmodium falciparum. Nature (2003) 7.72
Will women soon outrun men? Nature (1992) 5.17
Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol (1979) 3.32
Adverse drug reactions. BMJ (1998) 3.25
Recommendations on the use of exercise testing in clinical practice. Eur Respir J (2007) 3.15
A highly conserved enhancer in the Dlx5/Dlx6 intergenic region is the site of cross-regulatory interactions between Dlx genes in the embryonic forebrain. J Neurosci (2000) 2.98
Parameters of ventilatory and gas exchange dynamics during exercise. J Appl Physiol Respir Environ Exerc Physiol (1982) 2.29
Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol (1997) 2.26
Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet (1981) 2.25
The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS (1998) 2.16
Antidepressants and heart disease. Br Med J (Clin Res Ed) (1984) 2.14
Metabolic and respiratory profile of the upper limit for prolonged exercise in man. Ergonomics (1988) 2.12
Drug interactions with warfarin: studies with dichloralphenazone, chloral hydrate and phenazone (antipyrine). Clin Sci (1971) 2.11
Effect of interbreath fluctuations on characterizing exercise gas exchange kinetics. J Appl Physiol (1985) (1987) 2.06
Access to hematin: the basis of chloroquine resistance. Mol Pharmacol (1998) 2.03
4-Aminoquinolines--past, present, and future: a chemical perspective. Pharmacol Ther (1998) 2.00
An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. Contraception (1979) 1.97
Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol (1989) 1.97
A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine. J Steroid Biochem (1978) 1.90
Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J (2006) 1.87
Dose-dependent enzyme induction. Clin Pharmacol Ther (1973) 1.84
Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol (1984) 1.82
May mothers given warfarin breast-feed their infants? Br Med J (1977) 1.80
Rifampicin and vitamin D metabolism. Clin Pharmacol Ther (1980) 1.78
Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother (1997) 1.66
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS (1997) 1.65
Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol (2006) 1.64
Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet (1983) 1.64
The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol (1987) 1.63
Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet (1990) 1.63
Differential detection of transmissible gastroenteritis virus and porcine epidemic diarrhea virus by duplex RT-PCR. J Vet Diagn Invest (2001) 1.59
Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol (1988) 1.56
Phylogenetic analysis of swine influenza viruses recently isolated in Korea. Virus Genes (2008) 1.52
Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity. Clin Pharmacol Ther (1981) 1.52
Assessment of the drug metabolism capacity of the liver. Br J Clin Pharmacol (1982) 1.51
Dynamic asymmetry of phosphocreatine concentration and O(2) uptake between the on- and off-transients of moderate- and high-intensity exercise in humans. J Physiol (2002) 1.49
Influence of exercise intensity on the on- and off-transient kinetics of pulmonary oxygen uptake in humans. J Physiol (2001) 1.48
Inferences from pulmonary O2 uptake with respect to intramuscular [phosphocreatine] kinetics during moderate exercise in humans. J Physiol (1999) 1.48
Differentiation of a Vero cell adapted porcine epidemic diarrhea virus from Korean field strains by restriction fragment length polymorphism analysis of ORF 3. Vaccine (2003) 1.47
Drug disposition and drug hypersensitivity. Biochem Pharmacol (1987) 1.46
A study of the effect of anticoagulants on [3H]vitamin K1 metabolism and prothrombin complex activity in the rabbit. Biochem Pharmacol (1979) 1.46
Isolation and phylogenetic analysis of H1N1 swine influenza virus isolated in Korea. Virus Res (2006) 1.45
Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J (1992) 1.44
Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. J Cell Biol (1999) 1.44
Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS (1999) 1.44
Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci (2001) 1.43
The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol (1991) 1.42
The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS (1996) 1.41
The interaction of antibiotics with synthetic steroids in the rat [proceedings]. Br J Pharmacol (1978) 1.40
Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci U S A (2000) 1.40
Home based neuromuscular electrical stimulation as a new rehabilitative strategy for severely disabled patients with chronic obstructive pulmonary disease (COPD). Thorax (2002) 1.39
Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem Pharmacol (1997) 1.37
Interindividual variation and drug interactions with hormonal steroid contraceptives. Drugs (1981) 1.36
Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol (2003) 1.35
P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS (2001) 1.35
The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother (2004) 1.35
4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition. J Biol Chem (1996) 1.35
The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol (1990) 1.34
Effects of prior exercise on pulmonary gas-exchange kinetics during high-intensity exercise in humans. J Appl Physiol (1985) (1996) 1.33
The burden of alcohol misuse on an inner-city general hospital. QJM (2000) 1.31
Determination of primaquine in biological fluids by reversed-phase high-performance liquid chromatography. J Chromatogr (1984) 1.30
Relationship between antimalarial drug activity, accumulation, and inhibition of heme polymerization in Plasmodium falciparum in vitro. Antimicrob Agents Chemother (1998) 1.30
An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin. Br J Clin Pharmacol (1988) 1.29
Diamidine compounds: selective uptake and targeting in Plasmodium falciparum. Mol Pharmacol (2001) 1.29
Rapid chloroquine efflux phenotype in both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. A correlation of chloroquine sensitivity with energy-dependent drug accumulation. Biochem Pharmacol (1992) 1.29
Immediate decrease by hydrocortisone of the plasma half-life of antipyrine. Br J Pharmacol (1973) 1.28
Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol (1985) 1.27
Application of scanning electron microscopy in assessing the prevalence of some Setaria species in Korean cattle. Korean J Parasitol (1994) 1.27
Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol (1989) 1.27
Simultaneous determination of muscle 31P and O2 uptake kinetics during whole body NMR spectroscopy. J Appl Physiol (1985) (1999) 1.27
The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction. Br J Clin Pharmacol (1986) 1.26
Assessment of urinary 6 beta-hydroxycortisol as an in vivo index of mixed-function oxygenase activity. Br J Clin Pharmacol (1981) 1.26
Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols. Antimicrob Agents Chemother (1998) 1.26
Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol (1984) 1.26
Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob Agents Chemother (2006) 1.25
Physicochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum. Mol Pharmacol (1996) 1.25
The effects of food on drug bioavailability. Br J Clin Pharmacol (1989) 1.25
Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol (1998) 1.25
The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol (1990) 1.21
Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS (1999) 1.21
Cimetidine potentiates the anticoagulant effect of warfarin by inhibition of drug metabolism. Biochem Pharmacol (1980) 1.21
Prediction of metabolic drug interactions involving beta-adrenoceptor blocking drugs. Br J Clin Pharmacol (1984) 1.19
Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg (1991) 1.19
Vesicular stomatitis virus infection induces a nuclear DNA-binding factor specific for the interferon-stimulated response element. J Virol (1995) 1.19
Effects of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol (1984) 1.19